Life science research firm Biotium has launched its new range of Choice primary antibody conjugates. With careful curation, and extensive in-house validation, Biotium Choice monoclonal primary antibodies are designed to deliver exceptional performance for flow cytometry.
Biotium Choice antibody conjugates are available in a selection of CF Dyes, Astral Leap tandem dyes, and PE. CF Dyes are Biotium's unique fluorescent probes that offer exceptional brightness and signal-to-noise. Astral Leap tandem dyes are Biotium‘s new long Stokes shift dyes for enhanced multiplexing in flow cytometry. Featuring breakthrough chemical strategies to optimise both the Förster Resonance Energy Transfer (FRET) dye capabilities and conjugation to the fluorescent protein, Astral Leap tandem dyes provide expanded multiplexing options and exceptional signal-to-noise compared to other commercially available tandem dyes. RPE-Astral 616 and APC-Astral 813 are currently available for select Biotium Choice antibody conjugates with more tandem dyes on the way.
Biotium Choice primary antibody conjugates are currently available in several widely published clones against common targets including CD3e, CD4, CD8a, CD9, CD16, CD19, CD45, CD63, and CD81. Biotium intends to expand the catalogue significantly with more targets, label options, and validated applications.
The release of the Biotium Choice primary antibodies adds to Biotium’s growing catalog of robust and validated probes for life science research. To learn more about Biotium Choice primary antibodies as well as Biotium’s full selection of over 2000 monoclonal primary antibodies, visit www.biotium.com.